Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
|Articles|August 1, 1998
The American Journal of Managed Care
- August 1998
- Volume 4
- Issue 8
Correspondence regarding, "A Cost-Effectiveness Clinical Decision Analysis Model for Schizophrenia"
Advertisement
Articles in this issue
about 28 years ago
Identification and Assessment of High-Risk Seniorsabout 28 years ago
Outpatient Antidepressant Utilization in a Dutch Sick Fundabout 28 years ago
Inborn Errors of Metabolism: Medical and Administrative "Orphans"about 28 years ago
Generic Drug Product Equivalence: Current StatusAdvertisement
Related to this article
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.
A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
3
CMS Projects 16.5% Drop in 2027 Medicare Advantage Premiums
4
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
5